This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EC to keep eye on settlements, patent defence after pharma probe

By Lewis Crofts ( June 12, 2009, 15:06 GMT | Insight) -- The European Commission’s enquiry into the pharmaceuticals sector is set to result in a range of regulatory measures to ease the path for drugs coming to market, but possible competition enforcement is less clear with only suggestions of where DG Competition might focus its attention, according to a draft text. Defensive patenting strategies and agreements restricting generic entry seem to be of particular interest.The European Commission’s enquiry into the pharmaceuticals sector is set to result in a range of regulatory measures to ease the path for drugs coming to market, but possible competition enforcement is less clear with only suggestions of where DG Competition might focus its attention....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections